Circular RNA-based liquid biopsy: a promising approach for monitoring drug resistance in cancer [0.03%]
基于循环RNA的液体活检：监测癌症药物抵抗的新希望
Desh Deepak Singh,Dharmendra Kumar Yadav,Dongyun Shin
Desh Deepak Singh
Drug resistance remains a significant challenge in achieving successful cancer treatment, often leading to disease recurrence and reduced patient survival. While traditional tissue biopsies provide valuable insights into tumor biology, they...
CDK4/6 and BET inhibitors synergistically suppress pancreatic tumor growth and epithelial-to-mesenchymal transition by regulating the GSK3β-mediated Wnt/β-catenin pathway [0.03%]
CDK4/6和BET抑制剂通过调节GSK3β介导的Wnt/β-连环蛋白信号通路协同抑制胰腺肿瘤生长和上皮间质转化
Jiangning Gu,Zihao Dai,Tianci Shen et al.
Jiangning Gu et al.
Aim: Cyclin-dependent kinases 4 and 6 (CDK4/6) are frequently upregulated in pancreatic ductal adenocarcinoma (PDAC) and are associated with poor overall survival. Although CDK4/6 inhibition suppresses tumor cell proliferation, it paradoxic...
Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors [0.03%]
靶向脱泛素酶USP14克服卵巢癌顺铂耐药及新型抑制剂的发现
Cristina Corno,Debora Russo,Francesco Pignotti et al.
Cristina Corno et al.
Aim: This study aims to investigate the biological role of the proteasome-associated deubiquitinase ubiquitin-specific protease 14 (USP14) in ovarian carcinoma drug resistance and to identify novel USP14 inhibitors (USP14i) for further prec...
KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer [0.03%]
KLF5通过染色质重塑促进KRAS突变型结直肠癌肿瘤增殖和奥沙利铂耐药性
Zhuoqing Xu,Silei Sun,Han Gao et al.
Zhuoqing Xu et al.
Aim: Patients with KRAS-mutated colorectal cancer (CRC) frequently exhibit resistance to conventional chemotherapy and epidermal growth factor receptor (EGFR)-targeted therapies. This study investigates the role of the transcription factor ...
Cisplatin resistance in head and neck squamous cell carcinoma is linked to DNA damage response and cell cycle arrest transcriptomics rather than poor drug uptake [0.03%]
头颈鳞状细胞癌中顺铂耐药与DNA损伤反应和细胞周期停滞转录组学相关而非药物摄取不良有关
Ketaki Sandu,Rolf Warta,Uddipta Biswas et al.
Ketaki Sandu et al.
Aim: Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) is thought to involve both reduced drug uptake and altered molecular responses. However, the relative contribution of these mechanisms remains unclear. Methods: Two ...
Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies [0.03%]
免疫检查点抑制剂在肝细胞癌治疗中的耐药机制、肝脏移植挑战及管理策略
Yutao Chen,Desheng Chen,Zhixing Liang et al.
Yutao Chen et al.
Hepatocellular carcinoma (HCC) poses a significant clinical burden due to its aggressive nature, profound tumor heterogeneity, and limited therapeutic efficacy. While immune checkpoint inhibitors (ICIs) have revolutionized treatment paradig...
Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance [0.03%]
利用纳米药物靶向缺氧信号通路以逆转免疫治疗耐药性
Xiaoliang Cheng,Peixing Wang,Hongqiang Lyu et al.
Xiaoliang Cheng et al.
Immunotherapy has emerged as a major therapeutic strategy for cancer; however, immunotherapy resistance remains a significant challenge. Hypoxia, a key hallmark of the tumor microenvironment resulting from the imbalance between the high oxy...
Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells [0.03%]
阿特普酶6V0D1缺陷型胰腺癌细胞差异化诱导细胞死亡的隐密酮机制研究
Fangquan Chen,Junhao Lin,Xiutao Cai et al.
Fangquan Chen et al.
Aim: Dysregulation of tumor-suppressive pathways can lead to constitutive activation of multiple oncogenic signaling cascades. Such overactivation makes cancer cells highly dependent on these pathways, creating potential therapeutic vulnera...
Resistance signatures manifested in early drug response across cancer types and species [0.03%]
癌症类型和物种早期用药反应中表现的耐药标志物
Cole Ruoff,Allison Mitchell,Priya Mondal et al.
Cole Ruoff et al.
Aim: Growing evidence points to non-genetic mechanisms underlying long-term resistance to cancer therapies. These mechanisms involve pre-existing or therapy-induced transcriptional cell states that confer resistance. However, the relationsh...
Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer [0.03%]
整合基因组突变和肿瘤浸润淋巴细胞可改善HER2阳性乳腺癌患者曲妥珠单抗辅助治疗反应的预测能力
Shuangshuang Lu,Yuliang Zhang,Yiwei Tong et al.
Shuangshuang Lu et al.
Aim: Resistance to trastuzumab remains a major barrier to cure in early-stage HER2-positive breast cancer (HER2+ BC). We investigated the impact of genomic alterations and tumor-infiltrating lymphocyte (TIL) density on treatment resistance ...